The global Venous thromboembolism (VTE) Therapeutics market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The USA market for Global Venous thromboembolism (VTE) Therapeutics market is estimated to increase from USD million in 2022 to reach USD million by 2030, at a CAGR during the forecast period of 2023 through 2030.
The China market for Global Venous thromboembolism (VTE) Therapeutics market is estimated to increase from USD million in 2022 to reach USD million by 2030, at a CAGR during the forecast period of 2023 through 2030.
The Europe market for Global Venous thromboembolism (VTE) Therapeutics market is estimated to increase from USD million in 2022 to reach USD million by 2030, at a CAGR during the forecast period of 2023 through 2030.
Venous thromboembolism (VTE), which is composed of deep vein thrombosis (DVT) and pulmonary embolism (PE), is a blood clot (thrombosis) of the circulatory system that leads to impeded blood flow, which can have serious consequences in the affected individual (Heit, 2015). In VTE, a DVT is a clot that occurs only in the veins; generally, they occur in the deep veins of the legs and pelvis, but may also occur in the veins of the upper body (AHA, 2017; Cohen et al., 2007; Heit, 2015). The clot may break off from its original location and travel throughout the circulatory system, and if the clot ends up in the lung, it is known as a PE?
Venous thromboembolism Therapeutics Market aims to provide a comprehensive presentation of the global market for Venous thromboembolism (VTE) Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Venous thromboembolism (VTE) Therapeutics. Venous thromboembolism Therapeutics Market contains market size and forecasts of Venous thromboembolism (VTE) Therapeutics in global, including the following market information:
- Global Venous thromboembolism (VTE) Therapeutics Market Revenue, 2018-2023, 2024-2030, ($ millions)
- Global top five companies in 2022 (%)
One of the Major drivers of VTE market growth over the forecast period is the increase in patient shares towards the NOACs due to increased confidence among physicians about using these novel therapies.
We surveyed the Venous thromboembolism (VTE) Therapeutics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Venous thromboembolism (VTE) Therapeutics Market, by Type, 2018-2023, 2024-2030 ($ millions)
Global Venous thromboembolism (VTE) Therapeutics Market Segment Percentages, by Type, 2022 (%)
- Deep Vein Thrombosis(DVT)
- Pulmonary Embolism(PE)
- Others
Global Venous thromboembolism (VTE) Therapeutics Market, by Application, 2018-2023, 2024-2030 ($ millions)
Global Venous thromboembolism (VTE) Therapeutics Market Segment Percentages, by Application, 2022 (%)
- Hospital
- Ambulatory Surgery Centers
- Research Institutes
- Others
Global Venous thromboembolism (VTE) Therapeutics Market, By Region and Country, 2018-2023, 2024-2030 ($ Millions)
Global Venous thromboembolism (VTE) Therapeutics Market Segment Percentages, By Region and Country, 2022 (%)
- North America (United States, Canada, Mexico)
- Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe)
- Asia-Pacific (China, India, Japan, South Korea, Australia, Rest of APAC)
- The Middle East and Africa (Middle East, Africa)
- South and Central America (Brazil, Argentina, Rest of SCA)
Competitor Analysis
The report also provides analysis of leading market participants including:
- Key companies Venous thromboembolism (VTE) Therapeutics revenues in global market, 2018-2023 (estimated), ($ millions)
- Key companies Venous thromboembolism (VTE) Therapeutics revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
- Boehringer Ingelheim
- Bayer
- Janssen
- Bristol-Myers Squibb
- Pfizer
- Daiichi-Sankyo
- Portola Pharmaceuticals
- Armetheon
Outline of Major Chapters:
Chapter 1: Introduces the definition of Venous thromboembolism (VTE) Therapeutics, market overview.
Chapter 2: Global Venous thromboembolism (VTE) Therapeutics market size in revenue.
Chapter 3: Detailed analysis of Venous thromboembolism (VTE) Therapeutics company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Venous thromboembolism (VTE) Therapeutics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.